{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:16:38Z","timestamp":1777497398042,"version":"3.51.4"},"reference-count":39,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Rimegepant is an orally administered small\u2010molecule calcitonin gene\u2010related peptide (CGRP) receptor antagonist, with demonstrated efficacy in the acute treatment of migraine. Recent estimates from a single\u2010arm trial (BHV3000\u2010201) have also shown evidence of long\u2010term preventive effects in monthly migraine days (MMDs) and health\u2010related quality of life (HRQoL). This study aimed to compare MMDs and HRQoL data for oral rimegepant to those obtained in placebo\u2010controlled trials for injectable anti\u2010CGRP monoclonal antibodies (mAbs) galcanezumab and erenumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Matching\u2010adjusted indirect comparisons (MAICs) were conducted using rimegepant subject\u2010level data and published aggregate\u2010level results from mAb trials. Rimegepant baseline characteristics were matched to the pooled subject characteristics from EVOLVE\u2010I\/II (galcanezumab vs. placebo;\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a01773) and STRIVE (ereumab vs. placebo;\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0955) by reweighting the rimegepant subjects to more closely match the distributions observed in these trials. To align with inclusion criteria of the mAb trials, only the subset of rimegepant subjects with a history of 4\u201314 MMDs were included (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0257). Weighted mean differences were used to calculate adjusted change in MMDs, Migraine Disability Assessment Test (MIDAS) score, and Migraine\u2010Specific Quality of Life Questionnaire version 2 (MSQv2) scores from baseline to week 12.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When matched to the EVOLVE trials, rimegepant was superior to placebo with a mean difference in MMD change from baseline [95% confidence interval] of \u22121.16 [\u22121.80, \u22120.52] and was not statistically significantly different from galcanezumab 0.59 [\u22120.13, 1.32]. When matched to the STRIVE trial, rimegepant was superior to placebo \u22121.59 [\u22122.15, \u22121.03] and was not statistically significantly different from erenumab \u22120.06 [\u22120.61, 0.50]. Rimegepant showed superior MIDAS and MSQv2 results compared with placebo in both EVOLVE trials and in the STRIVE trial, no statistically significant differences from galcanezumab and erenumab regarding MIDAS, and favorable results compared with erenumab across all MSQv2 domains, while being generally similar to galcanezumab across all MSQv2 domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>When adjustments were made to reflect baseline characteristics in published literature, supporting data from BHV3000\u2010201 suggest that rimegepant every other day is an effective therapy in reducing disability and MMDs and enhancing migraine\u2010specific HRQoL. These data support the preventive benefit observed in randomized trials of rimegepant and further validate its efficacy for both acute and preventive treatment of migraine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14128","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T03:35:26Z","timestamp":1621654526000},"page":"906-915","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Matching\u2010adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health\u2010related quality of life in the treatment of migraine"],"prefix":"10.1111","volume":"61","author":[{"given":"Evan","family":"Popoff","sequence":"first","affiliation":[{"name":"Broadstreet Health Economics &amp; Outcomes Research Vancouver BC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karissa","family":"Johnston","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics &amp; Outcomes Research Vancouver BC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Thiry","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Harris","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Powell","sequence":"additional","affiliation":[{"name":"Broadstreet Health Economics &amp; Outcomes Research Vancouver BC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Coric","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals New Haven CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Moren","sequence":"additional","affiliation":[{"name":"The Headache Clinic Island Hospital Anacortes WA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e31812006365"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_9_9_1","unstructured":"LiptonRBCCM StockEG StockD et al.Efficacy safety and tolerability of rimegepant 75 mg an oral CGRP receptor antagonist for the acute treatment of migraine: results from a double\u2010blind randomized placebo\u2010controlled trial study 301. In: American Headache Society Meeting;2018."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"e_1_2_9_11_1","first-page":"1","article-title":"Long\u2010term, open\u2010label safety study of rimegepant 75 mg for the treatment of migraine (study 201): interim analysis of safety and exploratory efficacy (IHC\u2010PO\u2010127)","volume":"39","author":"Lipton RB","year":"2019","journal-title":"Cephalalgia"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30146-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0865-z"},{"issue":"15","key":"e_1_2_9_14_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.94.15_supplement.1793","article-title":"Rimegepant 75 mg results in reductions in monthly migraine days: secondary analysis of a multicenter, open label long\u2010term safety study of rimegepant for the acute treatment of migraine (1793)","volume":"94","author":"McGinley JS","year":"2020","journal-title":"Neurology"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_9_16_1","volume-title":"NICE DSU Technical Support Document 18","author":"Phillippo D","year":"2016"},{"key":"e_1_2_9_17_1","volume-title":"The Migraine Disability Assessment Test","author":"Innovative Medical Research","year":"2018"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2011.01997.x"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01127-0"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01143-0"},{"key":"e_1_2_9_21_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2019"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272431613503215"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/imamat\/6.3.222"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01393-2018"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418789072"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417731348"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0813-3"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12482"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13951"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2008.01217.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008589"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181974b19"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14128","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.14128","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T12:57:41Z","timestamp":1762088261000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1111\/head.14128"],"URL":"https:\/\/doi.org\/10.1111\/head.14128","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"2020-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}